{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.0","value":"220"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state.","dispersionType":"Standard Deviation","groups":[{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in Part 2 TGA and TGB","id":"OG000","title":"12mg QD INCB057643"}],"paramType":"MEAN","populationDescription":"PK evaluable population includes all subjects who received at least 1 dose of study drug and had at least 1 PK sample collected and analyzed","reportingStatus":"POSTED","timeFrame":"C2D1","title":"Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.","type":"SECONDARY","unitOfMeasure":"nM"}